Profile data is unavailable for this security.
About the company
Innovent Biologics Inc is an investment holding company principally engaged in biopharmaceuticals. The Company and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The Company's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkin’s lymphoma. The Company's products also include adalimumab biosimilar IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab biosimilar IBI-305 is used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). Rituximab biosimilar IBI-301 is used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its products are used in oncology, metabolic, immunology and ophthalmology diseases.
- Revenue in HKD (TTM)8.01bn
- Net income in HKD-1.38bn
- Incorporated2011
- Employees5.26k
- LocationInnovent Biologics Inc168Dongping Street, Suzhou Industrial ParkSUZHOU 215123ChinaCHN
- Websitehttps://www.innoventbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Resources Pharmaceutical Group Ltd | 269.14bn | 4.06bn | 33.49bn | 72.76k | 8.26 | 0.6445 | 2.70 | 0.1244 | 0.6455 | 0.6455 | 42.84 | 8.27 | 0.966 | 6.09 | 3.28 | 3,687,543.00 | 3.19 | 3.02 | 12.13 | 11.35 | 15.78 | 15.72 | 3.31 | 2.87 | 1.12 | 11.50 | 0.4396 | 24.73 | 12.16 | 8.86 | 10.11 | 2.80 | 13.58 | 7.05 |
| CSPC Pharmaceutical Group Ltd | 32.52bn | 5.54bn | 60.70bn | 20.30k | 11.08 | -- | 32.62 | 1.87 | 0.4685 | 0.4685 | 2.75 | -- | -- | -- | -- | 1,383,707.00 | -- | 16.08 | -- | 21.57 | 70.59 | 72.95 | 17.28 | 19.63 | -- | 25.15 | -- | 35.51 | 1.66 | 12.16 | -3.58 | 13.77 | -2.58 | 25.33 |
| Innovent Biologics Inc | 8.01bn | -1.38bn | 63.06bn | 5.26k | -- | 4.70 | -- | 7.87 | -0.8626 | -0.8626 | 5.00 | 8.20 | 0.3905 | 1.32 | 6.25 | 1,644,105.00 | -6.71 | -13.06 | -8.22 | -15.85 | 82.44 | 84.51 | -17.18 | -43.44 | 2.51 | -6.91 | 0.2123 | -- | 36.21 | 265.79 | 52.83 | -- | 34.60 | -- |
| Sino Biopharmaceutical Ltd | 28.78bn | 2.15bn | 63.51bn | 24.44k | 29.02 | 1.76 | 10.22 | 2.21 | 0.1165 | 0.2384 | 1.56 | 1.92 | 0.4050 | 2.37 | 3.74 | 1,115,435.00 | 7.42 | 13.11 | 14.50 | 21.74 | 82.92 | 80.37 | 18.33 | 27.47 | 1.07 | 18.13 | 0.1868 | 25.02 | 0.6657 | 4.63 | -10.29 | -27.22 | -7.18 | 1.15 |
| Holder | Shares | % Held |
|---|---|---|
| Temasek Holdings Pte Ltd. (Investment Management)as of 19 Aug 2024 | 129.84m | 7.94% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 53.46m | 3.27% |
| Capital Research & Management Co. (World Investors)as of 07 Nov 2024 | 43.28m | 2.65% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 32.57m | 1.99% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 32.46m | 1.99% |
| FIL Investment Management (Hong Kong) Ltd.as of 30 Sep 2024 | 31.11m | 1.90% |
| Capital International Ltd.as of 07 Nov 2024 | 30.53m | 1.87% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 25.72m | 1.57% |
| Capital International, Inc.as of 10 Jul 2024 | 22.48m | 1.38% |
| Schroder Investment Management Ltd.as of 30 Sep 2024 | 22.30m | 1.36% |
